 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This indicator may be signaling that PRLD's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Prelude Therapeutics (PRLD, $4.62) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This is a Bearish indicator signaling PRLD's price could decline from here. Traders may explore shorting the stock or put options...

Prelude Therapeutics (PRLD, $4.61) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 26, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Prelude Therapeutics initiated with bullish view at JMP Securities, here's why

Prelude Therapeutics (PRLD, $4.1) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 12, 2024

Prelude Therapeutics (PRLD, $4.1) entered Downtrend as Momentum indicator drops below 0 level on Mar 12, 2024

Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitorWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE...

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Prelude Therapeutics (PRLD, $4.22) entered Downtrend as Momentum indicator drops below 0 level on Mar 04, 2024

WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will...

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Prelude Therapeutics Incorporated (NASDAQ:PRLD  Free Report)  HC Wainwright lifted their Q1 2024 EPS estimates for shares of Prelude Therapeutics in a report issued on Tuesday, February...

Q1 2024 EPS Estimates for Prelude Therapeutics Incorporated (NASDAQ:PRLD) Raised by Analyst

HC Wainwright downgraded shares of Prelude Therapeutics (NASDAQ:PRLD  Free Report) from a buy rating to a neutral rating in a research note published on Tuesday, Marketbeat.com reports. They...

HC Wainwright Lowers Prelude Therapeutics (NASDAQ:PRLD) to Neutral

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Volume (M)	57,910.00
52-Wk High	$6.89
52-Wk Low	$1.66

PRLD Prelude Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals